FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to oncology, and can be used to determine the degree of aggressiveness of the course of skin melanoma. 16 or more factors affecting the prognosis of melanoma are identified and evaluated in points. The degree of aggressiveness of the course of the tumor process (S) is estimated in units according to the stated formula. When the value of S is up to 1.5 units, the I degree of aggressiveness is determined: life expectancy is more than 5 years. At S of 1.5-2 units, the II degree of aggressiveness: life expectancy of 2-5 years. With S greater than 2 units, the III degree of aggressiveness of skin melanoma and life expectancy of 1 year or less.
EFFECT: provides a clear definition of the degree of aggressiveness of the course of the disease by taking into account the most significant factors affecting the prognosis of skin melanoma.
1 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DETERMINING AGGRESSIVENESS OF LUNG CANCER | 2019 |
|
RU2724398C1 |
| METHOD OF PREDICTING DISEASE PROGRESSION OVER NEXT THREE MONTHS IN CANCER PATIENTS WITH SOLID TUMORS | 2022 |
|
RU2814841C2 |
| METHOD PREDICTING CLINICAL COURSE OF UVEA MELANOMA BASED ON APOPTHOSIS MARKER p53 | 2002 |
|
RU2208789C1 |
| METHOD FOR ADJUVANT THERAPY OF CANCER | 2013 |
|
RU2640180C2 |
| METHOD FOR PREDICTING CLINICAL DEVELOPMENT COURSE OF UVEAL MELANOMA | 2001 |
|
RU2192812C1 |
| METHOD FOR PREDICTING CLINICAL COURSE OF UVEAL MELANOMA DEVELOPMENT | 2001 |
|
RU2197731C2 |
| PREDICTION METHOD FOR LYMPHOMA CLINICAL COURSE SEVERITY AND TREATMENT EFFICIENCY | 2007 |
|
RU2345367C1 |
| METHOD FOR PREDICTION OF SURVIVAL RATE AFTER ENUCLEATION WITH UVEAL MELANOMA DEVELOPED TO EQUATOR | 2024 |
|
RU2822319C1 |
| METHOD FOR DETERMINING OVARIAN CANCER CLINICAL AGGRESSIVENESS | 2018 |
|
RU2688008C1 |
| BRAF KINASE INHIBITOR N-(3-(5-(4-CHLOROPHENYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-CARBONIL)-2,4-DIFLUOROPHENYL)PROPANE-1-SULFONAMIDE | 2018 |
|
RU2687107C1 |
